EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RBPJ is a novel target for rhabdomyosarcoma therapy



RBPJ is a novel target for rhabdomyosarcoma therapy



Plos One 7(7): E39268-E39268



The Notch pathway regulates a broad spectrum of cell fate decisions and differentiation processes during fetal and postnatal development. In addition, the Notch pathway plays an important role in controlling tumorigenesis. However, the role of RBPJ, a transcription factor in the Notch pathway, in the development of tumors is largely unknown. In this study, we focused on the role of RBPJ in the pathogenesis of rhabdomyosarcoma (RMS). Our data showed that Notch pathway genes were upregulated and activated in human RMS cell lines and patient samples. Inhibition of the Notch pathway by a γ-secretase inhibitor (GSI) decreased the in vitro proliferation of RMS cells. Knockdown of RBPJ expression by RNAi inhibited the anchorage-independent growth of RMS cells and the growth of xenografts in vivo. Additionally, overexpression of RBPJ promoted the anchorage-independent growth of RMS cells. Further, we revealed that RBPJ regulated the cell cycle in RMS xenograft tumors and decreased proliferation. Our findings suggest that RBPJ regulates the RMS growth, and that the inhibition of RBPJ may be an effective therapeutic approach for patients with RMS.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333683

Download citation: RISBibTeXText

PMID: 22792167

DOI: 10.1371/journal.pone.0039268



Related references

RBPJ May Be a More Effective Therapeutic Target Than NOTCH in GBM. Cancer Discovery 6(8): 817-817, 2016

EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding. Proceedings of the National Academy of Sciences of the United States of America 108(19): 7808-7813, 2011

NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proceedings of the National Academy of Sciences of the United States of America 111(2): 705-710, 2014

Neurog2 is a direct downstream target of the Ptf1a-Rbpj transcription complex in dorsal spinal cord. Development 136(17): 2945-2954, 2009

Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival. Cancer 119(8): 1578-1585, 2013

Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. International Journal of Radiation Oncology, Biology, Physics 59(4): 1027-1038, 2004

The Prdm13 histone methyltransferase encoding gene is a Ptf1a-Rbpj downstream target that suppresses glutamatergic and promotes GABAergic neuronal fate in the dorsal neural tube. Developmental Biology 386(2): 340-357, 2014

Late effects of therapy in orbital rhabdomyosarcoma in children. A report from the Intergroup Rhabdomyosarcoma Study. Cancer 57(9): 1738-1743, 1986

Late effects of therapy in patients with paratesticular rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. Journal of Clinical Oncology 10(4): 614-623, 1992

Prognostic significance of residual mass at the end of therapy in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS) IV experience. Journal of Clinical Oncology 23(16_suppl): 8501-8501, 2016

Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study. Journal of Clinical Oncology 7(2): 200-207, 1989

Radiation therapy for rhabdomyosarcoma: Local failure risk for Clinical Group III patients on Intergroup Rhabdomyosarcoma Study II. International Journal of Radiation Oncology Biology Physics 38(4): 797-804, 1997

Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. Journal of Clinical Oncology 18(12): 2427-2434, 2000